MCKESSON CORPORATION v. ANGEL BOLTON

CourtCourt of Appeals of Georgia
DecidedFebruary 12, 2026
DocketA25A2089
StatusPublished

This text of MCKESSON CORPORATION v. ANGEL BOLTON (MCKESSON CORPORATION v. ANGEL BOLTON) is published on Counsel Stack Legal Research, covering Court of Appeals of Georgia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
MCKESSON CORPORATION v. ANGEL BOLTON, (Ga. Ct. App. 2026).

Opinion

SECOND DIVISION RICKMAN, P. J., GOBEIL and DAVIS, JJ.

NOTICE: Motions for reconsideration must be physically received in our clerk’s office within ten days of the date of decision to be deemed timely filed. https://www.gaappeals.us/rules

February 12, 2026

In the Court of Appeals of Georgia A25A2089. MCKESSON CORPORATION v. BOLTON et al.

DAVIS, Judge.

In this action under the Drug Dealer Liability Act (“DDLA”), OCGA

§ 51-1-46, McKesson Corporation seeks interlocutory review of the trial court’s order

denying its motion to dismiss. McKesson argues that (1) the trial court erred in finding

that the general 20-year statute of limitation prescribed by OCGA § 9-3-22 applies to

the claims in this case instead of the 2-year statute of limitation for personal injuries

under OCGA § 9-3-33; and (2) it is immune from the DDLA as a licensed practitioner

acting in the course of its professional practice. We agree with McKesson that the

plaintiffs’ claims in this case under the DDLA are subject to the 2-year statute of limitation, and we accordingly reverse the trial court’s denial of McKesson’s motion

to dismiss.

On appeal of a trial court’s ruling on a motion to dismiss, our review is de novo. However, we construe the pleadings in the light most favorable to the plaintiff with any doubts resolved in the plaintiff’s favor. Our role is to determine whether the allegations of the complaint, when construed in the light most favorable to the plaintiff, and with all doubts resolved in the plaintiff’s favor, disclose with certainty that the plaintiff would not be entitled to relief under any state of provable facts.

Karekezi v. Pinnacle Systems, 367 Ga. App. 391, 391 (885 SE2d 235) (2023) (quotation

marks omitted).

According to the allegations of the operative complaint, Angel and Christopher

Bolton are the adult children of Kevin Bolton, who obtained prescriptions for opioids

and other controlled substances without a legitimate medical purpose. Kevin became

dependent upon controlled substances, and Angel and Christopher contend that this

addiction caused them physical, mental, emotional, and economic harm. Kevin

eventually overdosed and died on February 21, 2016.

Kevin obtained his prescriptions for opioids from Dr. Frank Bynes and filled his

prescriptions at Pembroke Pharmacy. McKesson is a pharmaceutical distributor that

2 distributed opioids to Pembroke Pharmacy. The dosages listed in the prescriptions

were over five times the daily dosage recommended by the Centers for Disease

Control to prevent overdose. In 2019, Dr. Bynes was convicted in federal court of

health care fraud and illegal dispensation of controlled substances, and Kevin’s father

testified at Dr. Bynes’ sentencing hearing. McKesson had a long-term relationship

with Pembroke Pharmacy, and the Boltons allege that Pembroke Pharmacy was

making excessive purchases of controlled substances and that McKesson did not

report these purchases to the Georgia Drug and Narcotics Agency pursuant to OCGA

§ 26-4-115.

Angel and Christopher filed their initial complaint on February 20, 2018,

against Dr. Bynes, Pembroke Pharmacy, and multiple other entities, but they did not

name McKesson as a defendant.1 On April 5, 2018, Angel and Christopher filed an

amended complaint, naming McKesson as a defendant for the first time, and they

eventually filed a fourth amended complaint raising a single claim under the DDLA.

McKesson moved to dismiss the claim against it, arguing among other things that (1)

1 The initial complaint listed a fictitious “John Doe Corporation” as a defendant, but the Boltons alleged that this fictitious corporation was Dr. Bynes’ employer. 3 the complaint was time barred, as the applicable two-year statute of limitation for

personal injury had run; and (2) the DDLA did not apply to it as a licensed distributor

of controlled substances.

The trial court granted the motion to dismiss in part and denied the motion to

dismiss in substantial part. The trial court first concluded that it was incapable of

determining whether McKesson is immune as a licensed distributor at the motion to

dismiss stage. As for the statute of limitation, the trial court first concluded that Angel

and Christopher’s amended complaint did not relate back under OCGA § 9-11-15 (c)

to the time the original complaint was filed, and it rejected Angel and Christopher’s

arguments as to tolling, so as a result it granted McKesson’s motion to dismiss certain

personal injury damages relating to the wrongful death of Kevin and his medical

expenses that were not paid by Angel and Christopher. However, the trial court

concluded that Angel and Christopher could seek recovery of the amount they spent

on Kevin’s healthcare and could seek non-economic damages under the DDLA that

would be unavailable otherwise in a traditional tort action because the 20-year statute

of limitation in OCGA § 9-3-22 applied to any part of their DDLA claim that was not

4 cognizable under standard tort law. We granted McKesson’s application for

interlocutory review.

1. McKesson first argues that this action is time-barred as the facts of this case

occurred more than two years before the Plaintiffs filed suit. McKesson argues that

the Boltons sought remedies for personal injury and the statute of limitation for such

actions is two years and that the trial court erred by applying the 20-year statute of

limitation of OCGA § 9-3-22. We agree.

Passed in 1997, the DDLA was intended to “provide a civil remedy for damages

to persons in a community injured as a result of illegal drug use.” OCGA § 51-1-46(b).

The DDLA was designed to “shift, to the extent possible, the cost of the damage

caused by the existence of an illegal drug market in a community to those who illegally

profit from that market.” Id. Under the Act, “[a] person injured by an individual drug

abuser may bring an action under this Code section for damages against a person who

participated in illegal marketing of the controlled substance used by the individual

abuser.” OCGA § 51-1-46(d)(1). The Act defines participating in illegal drug

marketing as “[m]anufacturing, distributing, or delivering or attempting or conspiring

to manufacture, distribute, or deliver, a controlled substance” in violation of state or

5 federal law. OCGA § 51-1-46(c)(9)(A). The DDLA does not contain its own statute

of limitation. See OCGA § 51-1-46.

OCGA § 9-3-33

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gropper v. STO CORP.
552 S.E.2d 118 (Court of Appeals of Georgia, 2001)
Daniel v. American Optical Corp.
304 S.E.2d 383 (Supreme Court of Georgia, 1983)
Teachers Retirement System of Ga. v. Plymel
676 S.E.2d 234 (Court of Appeals of Georgia, 2009)
Houston v. Doe
222 S.E.2d 131 (Court of Appeals of Georgia, 1975)
MUJKIC Et Al. v. LAM
804 S.E.2d 706 (Court of Appeals of Georgia, 2017)
Bigby v. Douglas
51 S.E. 606 (Supreme Court of Georgia, 1905)
Western Sky Financial, LLC v. State
793 S.E.2d 357 (Supreme Court of Georgia, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
MCKESSON CORPORATION v. ANGEL BOLTON, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mckesson-corporation-v-angel-bolton-gactapp-2026.